Clinical characteristics of ITP patient cohort: B-cell surface phenotypic analysis
| B-cell surface phenotypic analysis, patient no. . | Sex . | Age, y . | Treatment . | Platelet count, 109/L . |
|---|---|---|---|---|
| Off treatment, nonsplenectomized, platelet counts < 50 × 109/L | ||||
| 1 | M | 50 | No treatment | 24 |
| 2 | M | 56 | No treatment | 37 |
| 31 | M | 37 | No treatment | 5 |
| 42 | M | 69 | No treatment | 11 |
| 5 | M | 29 | No treatment | 38 |
| 6 | F | 67 | No treatment | 11 |
| 7 | F | 29 | No treatment | 13 |
| 8 | F | 18 | No treatment | 17 |
| 9 | F | 66 | No treatment | 38 |
| On treatment, nonsplenectomized, platelet counts > 50 × 109/L | ||||
| Same as 1 | M | 50 | On TPO agent | 94 |
| Same as 2 | M | 56 | On TPO agent | 64 |
| Same as 4 | M | 69 | On TPO agent plus danzol | 66 |
| Same as 5 | M | 29 | On TPO agent | 91 |
| Same as 9 | F | 66 | On TPO agent | 101 |
| 10 | F | 20 | On TPO agent | 181 |
| 11 | F | 54 | On TPO agent | 142 |
| 12 | F | 25 | On TPO agent | 102 |
| Off treatment, splenectomized, platelet counts < 50 × 109/L | ||||
| 133 | M | 54 | No treatment | 5 |
| 14 | M | 16 | No treatment | 27 |
| 15 | M | 15 | No treatment | 7 |
| 16 | F | 23 | No treatment | 32 |
| 17 | F | 38 | No treatment | 13 |
| 18 | M | 81 | No treatment | 35 |
| 19 | M | 57 | No treatment | 20 |
| 20 | M | 45 | No treatment | 21 |
| 21 | F | 31 | No treatment | 20 |
| On treatment, splenectomized, platelet counts > 50 × 109/L | ||||
| Same as 15 | M | 15 | On TPO agent | 340 |
| Same as 16 | F | 23 | On TPO agent | 204 |
| Same as 17 | F | 38 | On TPO agent | 89 |
| Same as 184 | M | 81 | On TPO agent | 52 |
| Same as 195 | M | 57 | On TPO agent | 133 |
| 22 | F | 20 | On TPO agent | 108 |
| 236 | F | 69 | On TPO agent | 126 |
| 24 | F | 73 | On TPO agent | 166 |
| 25 | M | 46 | On TPO agent | 214 |
| 26 | M | 20 | On TPO agent | 138 |
| B-cell surface phenotypic analysis, patient no. . | Sex . | Age, y . | Treatment . | Platelet count, 109/L . |
|---|---|---|---|---|
| Off treatment, nonsplenectomized, platelet counts < 50 × 109/L | ||||
| 1 | M | 50 | No treatment | 24 |
| 2 | M | 56 | No treatment | 37 |
| 31 | M | 37 | No treatment | 5 |
| 42 | M | 69 | No treatment | 11 |
| 5 | M | 29 | No treatment | 38 |
| 6 | F | 67 | No treatment | 11 |
| 7 | F | 29 | No treatment | 13 |
| 8 | F | 18 | No treatment | 17 |
| 9 | F | 66 | No treatment | 38 |
| On treatment, nonsplenectomized, platelet counts > 50 × 109/L | ||||
| Same as 1 | M | 50 | On TPO agent | 94 |
| Same as 2 | M | 56 | On TPO agent | 64 |
| Same as 4 | M | 69 | On TPO agent plus danzol | 66 |
| Same as 5 | M | 29 | On TPO agent | 91 |
| Same as 9 | F | 66 | On TPO agent | 101 |
| 10 | F | 20 | On TPO agent | 181 |
| 11 | F | 54 | On TPO agent | 142 |
| 12 | F | 25 | On TPO agent | 102 |
| Off treatment, splenectomized, platelet counts < 50 × 109/L | ||||
| 133 | M | 54 | No treatment | 5 |
| 14 | M | 16 | No treatment | 27 |
| 15 | M | 15 | No treatment | 7 |
| 16 | F | 23 | No treatment | 32 |
| 17 | F | 38 | No treatment | 13 |
| 18 | M | 81 | No treatment | 35 |
| 19 | M | 57 | No treatment | 20 |
| 20 | M | 45 | No treatment | 21 |
| 21 | F | 31 | No treatment | 20 |
| On treatment, splenectomized, platelet counts > 50 × 109/L | ||||
| Same as 15 | M | 15 | On TPO agent | 340 |
| Same as 16 | F | 23 | On TPO agent | 204 |
| Same as 17 | F | 38 | On TPO agent | 89 |
| Same as 184 | M | 81 | On TPO agent | 52 |
| Same as 195 | M | 57 | On TPO agent | 133 |
| 22 | F | 20 | On TPO agent | 108 |
| 236 | F | 69 | On TPO agent | 126 |
| 24 | F | 73 | On TPO agent | 166 |
| 25 | M | 46 | On TPO agent | 214 |
| 26 | M | 20 | On TPO agent | 138 |
Patients are subdivided based on their splenectomy status and their platelet counts (less than or more than 50 × 109/L). Some patients were also analyzed for B-cell surface phenotypic expression as well as functional studies on the same visit and they are indicated by the number followed by a numerical superscript. Patients' age and sex, as well as their platelet counts and the ITP treatment type on the day of the blood draw, are indicated. The exact B-cell subset frequencies for each patient are shown in supplemental Table 1 (available on the Blood Web site; see the Supplemental Materials link at the top of the online article).
ITP indicates immune thrombocytopenia; and TPO, thrombopoietic.